摘要
目的探究益气通脉方联合美托洛尔治疗冠心病心绞痛临床疗效及安全性。方法研究纳入132例冠心病心绞痛患者,均由医院2018年4月—2020年3月收治,以随机数字表法将其分为观察组和对照组,对照组患者(66例)给予美托洛尔治疗,观察组患者(66例)给予益气通脉方联合美托洛尔治疗,比较两组患者临床疗效、治疗前后患者心绞痛发作频率及心绞痛持续时间变化、中医症状(胸闷胸痛、气短、面色少华、倦怠乏力、舌黯红有瘀点、苔白脉弱等)积分变化、心输出量变化、血管内皮功能指标变化、血清炎症因子水平变化及血液流变学指标变化、不良反应。结果观察组患者治疗总有效率(96.97%,64/66)高于对照组(86.36%,57/66)(P<0.05);治疗前,两组患者心绞痛发作频率及心绞痛持续时间、胸闷胸痛、气短、面色少华、倦怠乏力、舌黯红有瘀点、苔白脉弱等中医症状积分、心输出量、血浆内皮素(ET-1)及一氧化氮(NO)血管内皮功能指标、C反应蛋白(CRP)及肿瘤坏死因子α(TNF-α)等炎症因子水平、纤维蛋白原(FIB)、全血黏度(WBV)、血浆黏度(PV)、血小板黏附率(PAR)等血液流变学指标比较,P>0.05,治疗后各组患者心绞痛发作频率及心绞痛持续时间、胸闷胸痛、气短、面色少华、倦怠乏力、舌黯红有瘀点、苔白脉弱等中医症状积分、心输出量、ET-1、NO、CRP、TNF-α、FIB、WBV、PV、PAR等指标均改善,观察组患者治疗后心绞痛发作频率及心绞痛持续时间、胸闷胸痛、气短、面色少华、倦怠乏力、舌黯红有瘀点、苔白脉弱等中医症状积分、心输出量、ET-1、NO、CRP、TNF-α、FIB、WBV、PV、PAR等指标均优于对照组(P<0.05);观察组患者无不良反应(0.00%),对照组出现1例恶心(1.52%)(P>0.05)。结论益气通脉方联合美托洛尔治疗冠心病心绞痛临床疗效显著,患者中医病症改善,心功能恢复好,无不良反应,安全性高,患者临床获益较高。
Objective To explore the clinical efficacy and safety of Yiqi Tongmai Prescription(益气通脉方) combined with metoprolol in the treatment of angina pectoris caused by coronary heart disease. Methods In this study, 132 patients with coronary heart disease and angina pectoris were admitted to our hospital from April 2018 to March 2020. They were divided into observation group and control group by random number table method. Patients in the control group(66 cases) were treated with metoprolol, while those in the observation group(66 cases) were treated with Yiqi Tongma Prescription combined with metoprolol. The clinical efficacy, frequency of angina pectoris attack and duration of angina pectoris before and after treatment, TCM symptoms(chest tightness, chest pain, shortness of breath, pale complexion, fatigue, dark red tongue with petechiae, white fur and weak pulse, etc.) integral changes, cardiac output changes, vascular endothelial function indexes changes, serum inflammatory factor levels and hemorheology indexes changes were compared between the two groups. The adverse reactions were compared. Results The total effective rate of the observation group(96.97%,64/66) was higher than that of the control group(86.36%,57/66)(P<0.05). Before treatment, the frequency of angina pectoris and duration of angina pectoris, chest tightness, chest pain, shortness of breath, pale complexion, fatigue, dark red tongue with petechiae, white fur, weak pulse and other TCM symptom scores, cardiac output, plasma endothelin-1(ET-1) and nitric oxide(NO), vascular endothelial function index, C-reactive protein(CRP),tumor necrosis factor-α(TNF-α),inflammatory factors, fibrinogen(FIB), whole blood viscosity(WBV), plasma viscosity(PV), platelet adhesion rate(PAR) and other hemorheological indexes of the two groups were compared(P>0.05). After treatment, the frequency of angina pectoris attack, duration of angina pectoris, chest tightness, chest pain, shortness of breath, pale complexion, fatigue, dark red tongue with petechiae, white fur, weak pulse and other TCM symptom scores, cardiac output, ET-1, NO, CRP, TNF-α,FIB, WBV, PV, PAR and other indicators were improved. In the observation group, those indexes were better than those of the control group(P<0.05). There was no adverse reaction in the observation group(0.00%), and 1 case of nausea in the control group(1.52%)(P>0.05). Conclusion Yiqi Tongmai Prescription combined with metoprolol has a significant clinical effect in the treatment of angina pectoris caused by coronary heart disease.
作者
马艳梅
李琳
MA Yanmei;LI Lin(Affiliated Hospital of Qinghai University,Xining 810000,Qinghai,China)
出处
《中华中医药学刊》
CAS
北大核心
2021年第9期173-176,共4页
Chinese Archives of Traditional Chinese Medicine
基金
青海省科技厅项目(2017-SF-L2)。
关键词
冠心病心绞痛
益气通脉方
美托洛尔
疗效
安全性
中医症状
coronary heart disease angina pectoris
Yiqi Tongmai Prescription(益气通脉方)
metoprolol
curative effect
security
symptoms of traditional Chinese medicine
